{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Stable Disease (SD) or Progressive Disease (PD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"To determine the efficacy of oral clofarabine (3mg) in patients with relapsed/refractory non-Hodgkin lymphoma. The 3mg dose was declared the recommended phase 2 dose (RP2D) from phase I.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Phase I"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase I participants only who were treated at the RP2D (3mg)","reportingStatus":"POSTED","timeFrame":"after at most 6 28-day cycles","title":"Phase I Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}